The structure of Tirzepatide extends its half-life to approximately 5 days by introducing -aminoisobutyric acid (Aib) to replace alanine at positions 2 and 13 to prevent DPP-4 degradation, and by covalently binding to a C20 eicosanedioic acid via a Glu-(AEEA-AEEA) linker at position 20 lysine residue, enabling once-weekly dosing
PlexusDx tirzepatide injections are manufactured by licensed 503A compounding pharmacies using identical active pharmaceutical ingredients and stability protocols as commercial products
Common side effects that affect many people include nausea, vomiting, stomach upset, diarrhea, stomach pain, and decreased appetite
Some patients see 23 pounds in the first month
Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., & Apostolakos, J